Cecropia obtusifolia (Urticaceae) Guarumo Blanco, Trumpet Tree, Hormiguillo
Cecropia obtusifolia is a Neotropical tree with a rare distinction in this series: it has been the subject of a human clinical trial for its traditional antidiabetic use. A 32-week study in 12 recently diagnosed type 2 diabetic patients found that daily aqueous leaf extract significantly reduced serum glucose after 4 weeks, with the reduction becoming sustained after 18 weeks, and HbA1c significantly reduced after 6 weeks, with no adverse effects reported . This clinical evidence is supported by mechanistic studies demonstrating inhibition of hepatic gluconeogenesis via glucose-6-phosphatase inhibition (IC50 224 μg/mL for the aqueous extract) and a dual action involving insulin secretion promotion and hepatoprotection in diabetic mice . The plant also has documented analgesic, anti-inflammatory, and central nervous system depressant activities , alongside traditional uses for rheumatic and kidney inflammation. However, the clinical trial was small (n=12) and open-label, and no large-scale randomized controlled trials exist.
---
1. Taxonomic Insights
Species: Cecropia obtusifolia Bertol.
Family: Urticaceae (Nettle Family; formerly placed in Cecropiaceae)
Genus: Cecropia
Taxonomic Note: The genus Cecropia has historically been placed in its own family, Cecropiaceae, but is now widely treated within Urticaceae. The species is one of several Cecropia species used interchangeably in Mexican traditional medicine for diabetes, alongside C. peltata .
---
Botanical Description
Cecropia obtusifolia is a fast-growing, dioecious tree reaching 10 to 20 metres in height, with a characteristic umbrella-like crown and hollow internodes often inhabited by Azteca ants in a mutualistic relationship.
Key Identification Features:
Leaves are large, peltate (stalk attached to the center of the blade rather than the edge), and palmately lobed, with a silvery-white underside. The species epithet obtusifolia refers to the blunt leaf tips. Inflorescences are finger-like spikes. The common name "guarumo blanco" (white guarumo) is used in Panama and Costa Rica .
Distribution: Native to Mexico and Central America, from Mexico through Guatemala to Panama. It is a pioneer species in disturbed habitats and forest edges.
Conservation Status: Not assessed as threatened. Widely distributed and locally common.
---
Etymology
The generic name Cecropia is derived from Cecrops, the mythical first king of Athens, possibly referring to the tree's resemblance to an umbrella or its use in traditional medicine. The specific epithet obtusifolia is Latin for "blunt-leaved."
---
2. Common Names
Scientific Name: Cecropia obtusifolia | English: Trumpet Tree, Guarumo | Spanish: Guarumo Blanco, Hormiguillo, Chancarro | Panama/Costa Rica: Guarumo Blanco | Mexico: Guarumbo, Hormiguillo
---
3. Related Herbs from the Urticaceae Family
Cecropia peltata: A closely related species used interchangeably in Mexican traditional medicine for diabetes. It shares the same active constituents (chlorogenic acid and isoorientin) and demonstrated similar gluconeogenesis inhibition in the same study .
Urtica dioica (Stinging Nettle): The most famous medicinal Urticaceae, with well-documented anti-inflammatory and diuretic properties. It shares the family's tendency toward phenolic-rich leaves.
The Urticaceae family is characterized by the presence of phenolic acids (particularly chlorogenic acid), flavonoids, and in some species, stinging trichomes.
---
4. Medicinal Uses: Summary of Primary and Secondary Actions
Primary Actions:
Antidiabetic / Hypoglycemic (Leaves): This is the most rigorously studied activity, with human clinical evidence. A 32-week open-label trial in 12 type 2 diabetic patients found significant glucose reduction after 4 weeks, sustained after 18 weeks, and HbA1c reduction after 6 weeks, with no adverse effects and no changes in insulin levels . Mechanistically, the aqueous extract inhibits glucose-6-phosphatase (IC50 224 μg/mL), reducing hepatic glucose output , and in diabetic mice promotes insulin secretion, increases liver glycogen storage, and exerts hepatoprotective effects via PPAR-α .
Analgesic (Leaves): The aqueous extract showed significant analgesic activity in chemical pain models (acetic acid and formalin tests) but not in the hot plate test, suggesting a peripheral mechanism. No effect was observed on thermal pain .
Anti-inflammatory (Leaves): The extract demonstrated both topical and systemic anti-inflammatory effects in animal models, including carrageenan-induced paw edema and TPA-induced ear edema . The hydroalcoholic extract reduced TNF-α and IL-6 while increasing IL-10 in renal inflammation models .
Secondary Actions:
· Antihypertensive / Vasorelaxant: Fractions of C. obtusifolia induced concentration-dependent relaxation in rat aorta (57.3% and 53.3% for the most active fractions) and inhibited angiotensin II and endothelin-1 contractile responses .
· Central Nervous System Depressant: The aqueous extract produced substantial central depressor effects and motor incoordination in animal models .
· Diuretic: A slight diuretic effect (20% increase in urinary flow) was observed in rats at 500 mg/kg daily for 7 days, potentially contributing to antihypertensive action .
· Hypolipidemic: In diabetic mice, the extract reduced triglycerides and improved lipid metabolism via PPAR-α .
---
Medicinal Parts
Leaves: The primary medicinal part, used as a cold infusion ("agua de uso") consumed over the course of a day . Source of chlorogenic acid, isoorientin, and other phenolics.
Bark and Roots: Used in traditional medicine for other purposes, but not the focus of modern pharmacological research.
---
5. Phytochemistry
5.1 Phenolic Acids and Flavonoids (Leaves)
The main constituents confirmed by HPLC-DAD are chlorogenic acid and isoorientin . These compounds are associated with the hypoglycemic and anti-inflammatory activities. Other identified compounds include catechin, epicatechin, isoquercitrin, procyanidin B2, and procyanidin C1 . Eleven compounds were isolated and elucidated from leaves by HRMS and NMR .
5.2 Other Compounds (Leaves)
Nineteen additional compounds have been identified, including five anthraquinones (aloe-emodin, emodin, rhein, chrysophanol, physcion), two saturated fatty acids (palmitic and stearic acid), five steroids (β-sitosterol, stigmasterol, stigmast-4-en-3-one, and others), and vanillic acid . Notably, these compounds are not related to the traditional use and are not commercially available, suggesting they are not the primary active principles .
---
6. Mechanisms of Action
6.1 Antidiabetic Activity
Two complementary mechanisms have been elucidated:
· Gluconeogenesis inhibition: Chlorogenic acid inhibits glucose-6-phosphate translocase, reducing hepatic glucose production. The aqueous extract inhibited glucose-6-phosphatase activity with IC50 224 μg/mL, supporting reduced hepatic glucose output, particularly in the fasting state .
· Insulin secretion and hepatoprotection: In RINm5F cells, the extract increased intracellular calcium and insulin secretion. In diabetic mice, it increased liver glycogen storage and glycogen synthase levels, increased PPAR-α and ACSL-1 expression, reduced triglycerides and transaminases, and modulated inflammatory cytokines (increased adiponectin and IL-10, decreased TNF-α) .
6.2 Anti-inflammatory Activity
The extract inhibits inflammatory pathways, reducing TNF-α and IL-6 and increasing IL-10 in renal inflammation models . The vasorelaxant and antihypertensive effects are attributed to inhibition of angiotensin II and endothelin-1 contractile responses .
---
7. Traditional and Ethnobotanical Uses
7.1 Diabetes (Leaves, Mexican Traditional Medicine)
Formulation: Cold infusion ("agua de uso") of the leaves, consumed over the course of a day .
Preparation and Use: The plant is highly used by the Mexican diabetic population to treat type 2 diabetes. The cold infusion is consumed throughout the day .
Scientific Validation: Supported by a human clinical trial demonstrating significant and sustained glucose and HbA1c reduction , alongside mechanistic studies confirming gluconeogenesis inhibition and insulin secretion promotion .
7.2 Rheumatic and Kidney Inflammation
Formulation: Aqueous extract of leaves.
Preparation and Use: Used in traditional medicine for rheumatic and kidney inflammation pathologies .
Scientific Validation: The analgesic and anti-inflammatory effects demonstrated in animal models justify this popular use .
7.3 Heart Failure, Cough, Asthma, and Bronchitis
Formulation: Various preparations.
Preparation and Use: C. obtusifolia, like many Cecropia species, shares the folk reputation of curing heart failure, cough, asthma, and bronchitis .
Scientific Validation: The vasorelaxant effect and inhibition of angiotensin II contractile responses provide a plausible mechanism for cardiovascular uses , but no clinical studies for respiratory conditions were found.
---
8. Healing Recipes, Teas, Decoctions, and Culinary Uses
8.1 Traditional Cold Infusion ("Agua de Uso") for Diabetes
Purpose: Traditional preparation for managing blood sugar.
Preparation and Use: A cold infusion of the leaves is prepared and consumed over the course of a day, as documented in Mexican traditional medicine . The clinical trial used an aqueous extract administered daily .
Scientific Validation: Supported by human clinical trial data showing significant glucose and HbA1c reduction .
---
9. Clinical Significance and Evidence Summary
9.1 Evidence Hierarchy by Activity
Antidiabetic (Leaves): Human clinical evidence from a 32-week open-label trial in 12 type 2 diabetic patients. Significant glucose reduction after 4 weeks, sustained after 18 weeks; HbA1c reduction after 6 weeks; no adverse effects; glucose and HbA1c rebounded after discontinuation . This is among the strongest clinical evidence bases for any species in this series, though the trial was small and uncontrolled.
Analgesic / Anti-inflammatory (Leaves): Moderate evidence from in vivo animal studies. Peripheral analgesic effect and topical/systemic anti-inflammatory effects demonstrated .
Antihypertensive / Vasorelaxant (Leaves): Moderate evidence from in vitro and animal studies. Vasorelaxation and inhibition of angiotensin II/endothelin-1 responses demonstrated .
Critical Gap: No large-scale, randomized, placebo-controlled trials exist. The clinical trial was open-label with 12 patients, and independent replication is needed.
---
10. Safety and Toxicology
10.1 Toxicity Profile
Leaves (Aqueous Extract): Low toxicity profile. No statistically significant cytotoxicity or genotoxicity was found in the SMART test in flies or the human micronucleus assay from lymphocytes of type 2 diabetes patients . Acute toxicity in mice reported an LD50 of 1450 ± 70 mg/kg (equivalent to 11.21 ± 0.52 g of plant/kg body weight) .
Clinical Safety: In the 32-week human trial, no adverse effects were observed, and no significant changes in ALT, AST, or ALKP were detected .
10.2 Contraindications and Precautions
Pregnancy and Lactation: No safety data exist. Consult a healthcare provider.
Diabetes Medications: The plant has demonstrated significant hypoglycemic activity. Additive effects with insulin or oral hypoglycemics are theoretically possible, and blood glucose should be monitored if combined.
10.3 Potential Drug Interactions
No formal drug interaction studies were found. Based on the demonstrated hypoglycemic mechanism , there is a theoretical potential for additive blood sugar lowering with antidiabetic medications.
---
11. Quality Control Parameters
11.1 Marker Compounds for Standardisation
For Leaves: Chlorogenic acid and isoorientin are the main constituents confirmed by HPLC-DAD and are associated with the hypoglycemic activity . These are the most suitable markers for standardizing extracts.
11.2 Recommended Analytical Methods
HPLC-DAD for quantification of chlorogenic acid and isoorientin, as used in the mechanistic studies . HPLC-DAD-QTOF for comprehensive polyphenolic profiling .
11.3 Suggested Specifications
No official pharmacopoeial specifications exist. For research-grade leaf extracts, specifications would include minimum chlorogenic acid content and verified glucose-6-phosphatase inhibitory activity.
---
12. Cultivation and Sustainability
12.1 Growth Requirements
Climate: Tropical. A pioneer species adapted to disturbed habitats and forest edges.
Habitat: Native to Mexico and Central America.
Propagation: Not detailed in the search results.
12.2 Sustainable Harvesting
Leaves are the primary harvest for medicinal use. The tree is fast-growing and common, suggesting sustainable harvest is feasible.
12.3 Conservation Status
Not assessed as threatened. Widely distributed as a pioneer species.
---
13. Research Gaps and Future Directions
13.1 Critical Research Gaps
Larger Clinical Trials: The 2007 trial was open-label with only 12 patients. Randomized, placebo-controlled trials with larger sample sizes are needed to confirm efficacy and establish optimal dosing .
Active Compound Isolation: While chlorogenic acid and isoorientin are the main constituents, the specific contributions of each to the hypoglycemic effect require further study.
Long-Term Safety: The 32-week trial provides some safety data, but longer-term studies are lacking.
Mechanism of Insulin Secretion: The clinical trial concluded that the hypoglycemic effect is not mediated by stimulating insulin secretion , yet a 2020 animal study found increased insulin secretion in RINm5F cells . This discrepancy requires clarification.
13.2 Future Research Priorities
Randomized Controlled Trial: A double-blind, placebo-controlled trial in type 2 diabetic patients, building on the promising open-label data.
Standardized Extract Development: Development of a standardized extract with defined chlorogenic acid and isoorientin content for use in future trials.
---
14. Commercial Applications
14.1 Pharmaceutical and Nutraceutical Potential
Antidiabetic Phytopharmaceutical (Promising): The combination of human clinical evidence, mechanistic data, and low toxicity profile positions C. obtusifolia as a strong candidate for development as a phytomedicine for type 2 diabetes .
14.2 Application-Specific Product Development
Standardized Leaf Extract: Capsules or powders standardized to chlorogenic acid and isoorientin for blood sugar support, pending larger clinical trials.
---
15. Related Plants for Further Study
Cecropia peltata: Used interchangeably with C. obtusifolia for diabetes and demonstrated similar gluconeogenesis inhibition (IC50 146 μg/mL for aqueous extract) . Comparative clinical studies would clarify whether the two species are truly interchangeable.
---
16. Reference Literature
Primary Research
· Revilla-Monsalve, M.C., et al. (2007). "Hypoglycemic effect of Cecropia obtusifolia Bertol aqueous extracts on type 2 diabetic patients." Journal of Ethnopharmacology 111(3): 636-640. Key human clinical trial .
· Andrade-Cetto, A., et al. (2010). "Gluconeogenesis inhibition and phytochemical composition of two Cecropia species." Journal of Ethnopharmacology 130(1): 93-97. Mechanistic study on glucose-6-phosphatase inhibition .
· Pérez-Guerrero, C., et al. (2001). "A pharmacological study of Cecropia obtusifolia Bertol aqueous extract." Journal of Ethnopharmacology 76(3): 279-284. Analgesic, anti-inflammatory, and CNS depressant data .
· (2020). "Mechanism of the Hypoglycemic Activity and Hepatoprotective Effect of the Aqueous Extract of Cecropia obtusifolia Bertol." Journal of Medicinal Food 23(7): 783-792. Insulin secretion and hepatoprotection data .
Key Monographs and Floras
· PubMed/PMC: Multiple studies available .
· ScienceDirect: Vasoactive effects study .
· BVS: Phytochemical and ethnobotanical data .
---
17. Disclaimer
The leaves of Cecropia obtusifolia have been used traditionally for diabetes and have demonstrated significant hypoglycemic effects in a small human clinical trial with no adverse effects reported.
This information is for educational and academic purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
The clinical evidence, while promising, comes from a small open-label trial. Larger randomized controlled trials are needed before C. obtusifolia can be recommended as a treatment for diabetes.
Individuals with diabetes should not replace prescribed medications with this plant without consulting a healthcare provider. Blood glucose should be monitored closely if combining with antidiabetic medications due to the potential for additive effects.
Proper identification is crucial. Always consult a qualified healthcare practitioner before using any plant for medicinal purposes.

Comments